Baudax Bio "announced that the Company’s Board of Directors has approved a 1-for-40 reverse stock split of its common shares. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on December 1, 2022 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol "BXRX". Baudax Bio expects that the Reverse Stock Split, which was approved by shareholders at a special shareholder meeting on November 3, 2022, will increase the market price per share of the Company’s common stock, bringing the Company into compliance with listing requirements of the $1.00 minimum bid price requirement by The Nasdaq Capital Market."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BXRX:
